
Denmark sliced its 2025 economic growth forecast in half recently after a cool-down at Novo Nordisk, the maker of diabetes drugs Ozempic and Wegovy, which have become popular among those wanting to quickly shed some pounds.
The dip in its growth forecast from 3% to 1.4% comes in large part due to weaker expectations for pharmaceutical giant Novo Nordisk—after the economy expanded by 3.7% last year due to a major boost from pharmaceutical exports.